CEO, at GeneOne Life Science, Inc, South Koreađź“–
Young K. Park is an accomplished executive and leader with a diverse background in law, economics, and business management. As the CEO and a member of the Board of Directors at GeneOne Life Science, Inc., and VGXI, Inc., Park has significantly contributed to the biopharmaceutical industry with expertise in vaccine development and clinical research. With a rich educational foundation and extensive professional experience, Park has driven significant advancements in health technology, contributing to international efforts in infectious disease management. His leadership has earned him multiple prestigious awards, and he remains a key figure in global health organizations, shaping the future of biopharmaceutical innovation.
Scopus Profile
Education Background🎓
Young K. Park has a strong academic foundation that blends law, economics, and business management. He earned his Bachelor of Arts in Economics from Dickinson College in 1987, where he developed a keen understanding of economic principles. Following this, Park pursued a Juris Doctor (J.D.) at the University of Pennsylvania Law School, completing his degree in 1990, which equipped him with a legal expertise that complements his leadership in business. To further expand his knowledge in finance, he obtained a Master of Science in Finance and Applied Economics from the MIT Sloan School of Management in 1992. This combination of legal, economic, and financial education has been integral to his successful career in the biopharmaceutical industry and his role in driving innovations in vaccine development.
Professional Experience🌱
Young K. Park has built a distinguished career in the biopharmaceutical industry, currently serving as the Chief Executive Officer (CEO) and a Board Member at both GeneOne Life Science, Inc. and VGXI, Inc. In these roles, he has overseen the strategic direction and growth of the companies, focusing on advancing cutting-edge vaccine development and production. Park’s leadership has been pivotal in establishing GeneOne as a key player in the global vaccine market, particularly in the development of DNA vaccines for infectious diseases. Beyond his corporate roles, Park has held significant advisory positions, including serving on expert panels for the World Health Organization (WHO) on MERS and Zika virus outbreaks, and collaborating with institutions like the Walter Reed National Military Medical Center and the International Vaccine Institute. His contributions to the field have been recognized through numerous awards, such as the Korea’s Leadership Technology Innovation Award and the Best Contract Manufacturing Organization Award at the World Vaccine Congress. His professional journey reflects a commitment to scientific innovation, public health, and leadership in the biopharmaceutical sector.
Research Interests🔬
Young K. Park has been at the forefront of innovative vaccine research, with particular interest in DNA vaccines for infectious diseases, including chronic hepatitis C, COVID-19, and Severe Fever with Thrombocytopenia Syndrome. His work has also focused on mRNA vaccine platforms and the development of nano-convergence technologies for improving vaccine efficacy. Park’s research has contributed to global health initiatives, with an emphasis on rapid vaccine development in response to emerging diseases such as Zika and Disease X.
Author MetricsÂ
- Park has authored and co-authored multiple high-impact publications related to vaccine development and infectious disease research.
- He has led research efforts funded by the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, Republic of Korea.
- Key projects include Phase I clinical development of DNA vaccines, as well as preclinical vaccine development for emerging diseases, such as Zika and COVID-19.
Publications Top Notes đź“„
1. Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
- Authors: Chung, C., Kudchodkar, S.B., Chung, C.N., Abdel-Mohsen, M., Muthumani, K.
- Journal: Antibodies, 2023
- Volume: 12, Issue 3
- Article Number: 46
- Summary: This review paper explores the potential of synthetic nucleic acid delivery systems, such as DNA and mRNA, in enhancing monoclonal antibody-based immunotherapies. The paper focuses on novel methods of nucleic acid delivery, which could improve therapeutic efficacy and broaden the application of monoclonal antibodies in the treatment of various diseases.
2. DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond
- Authors: Maslow, J.N., Kwon, I., Kudchodkar, S.B., Muthumani, K., Roberts, C.C.
- Journal: Vaccines, 2023
- Volume: 11, Issue 6
- Article Number: 1016
- Summary: This paper discusses the role of DNA vaccines in epidemic preparedness, focusing on SARS-CoV-2 and other emerging infectious diseases. It highlights the advantages of DNA vaccines, including their rapid development and scalability, and examines their potential for use in future pandemics.
3. Safety and Immunogenicity of the Bi-Cistronic GLS-5310 COVID-19 DNA Vaccine Delivered with the GeneDerm Suction Device
- Authors: Kim, W.J., Roberts, C.C., Song, J.Y., Jeong, M., Maslow, J.N.
- Journal: International Journal of Infectious Diseases, 2023
- Volume: 128
- Pages: 112–120
- Summary: This study evaluates the safety and immunogenicity of the bi-cistronic GLS-5310 DNA vaccine, which targets COVID-19, when delivered using the GeneDerm suction device. The findings support the feasibility of using this novel delivery method for improved immune responses to the vaccine.
4. Immune Responses of a Novel Bi-Cistronic SARS-CoV-2 DNA Vaccine Following Intradermal Immunization With Suction Delivery
- Authors: Jeong, M., Kudchodkar, S.B., Gil, A., Roberts, C.C., Maslow, J.N.
- Journal: Frontiers in Virology, 2022
- Volume: 2
- Article Number: 891540
- Summary: This paper investigates the immune responses elicited by a bi-cistronic SARS-CoV-2 DNA vaccine administered intradermally using a suction delivery system. The study demonstrates the potential of this innovative delivery method for enhancing vaccine efficacy.
5. Novel Suction-Based In Vivo Cutaneous DNA Transfection Platform
- Authors: Lallow, E.O., Jhumur, N.C., Ahmed, I., Maslow, J.N., Lin, H.
- Journal: Science Advances, 2021
- Volume: 7, Issue 45
- Article Number: eabj0611
- Summary: This research introduces a novel suction-based in vivo cutaneous DNA transfection platform, which allows for efficient DNA delivery to the skin. The paper discusses the advantages of this technology in terms of its application for gene therapies and vaccine delivery.
Conclusion
Mr. Young Kun Park is a visionary leader whose multidisciplinary expertise and groundbreaking contributions to the biopharmaceutical industry, particularly in vaccine development, position him as a deserving candidate for the Best Researcher Award. His innovative approach, coupled with a strong focus on public health, has not only contributed to the advancement of biopharmaceutical sciences but also helped shape global responses to emerging infectious diseases. With continued growth in collaborative networks, sustainability efforts, and equitable access strategies, Mr. Park’s future research endeavors will undoubtedly drive further transformation in the healthcare and vaccine development sectors.